newsfilter
← Latest News
GlobeNewswire·

Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program

- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer's Disease - - IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed to proceed with